Recce secures funding to fight antibiotic-resistant superbugs
Funding from New York-based asset manager, The Lind Partners.
Company
Recce Pharmaceuticals Ltd
ASX:RCE
Recce Pharmaceuticals Ltd (ASX:RCE) is developing a new class of synthetic anti-infectives designed to address the urgent global health threat of antibiotic-resistant superbugs.
169 stories · page 9 of 9
Recce moves closer to clinical study application in the U.S.
Superbugs are widely acknowledged as a threat to human and animal health.
Recce continues to make progress against antibiotic-resistant superbugs
Intravenous infusion of Recce’s lead compound was well tolerated.
Recce’s compound shows promising results against superbugs
Recce (ASX:RCE) has received positive early results for its lead product candidate RECCE 327 as a potential treatment against drug resistant E. coli bacteria.
Recce’s anti-cancer compound appears to be well tolerated
Recce Ltd’s (ASX:RCE) share price has increased after receiving positive toxicology results from a dose escalation study of its lead compound RECCE 327, in a mouse with cancer.